HIV prevention drug lenacapavir safe and effective in trial

A Phase 3 clinical trial found lenacapavir, a novel injectable HIV prevention drug, to be safe and 100% effective when administered twice a year to cisgender women. This breakthrough could revolutionize HIV prevention strategies, potentially reducing new infections significantly. Lenacapavir inhibits HIV replication by targeting the virus's capsid protein. The drug's bi-annual dosing schedule simplifies prevention regimens. Regulatory approvals and pricing remain key challenges for widespread implementation.